Comorbidity in patients with cancer treated at The Christie.
Journal
British journal of cancer
ISSN: 1532-1827
Titre abrégé: Br J Cancer
Pays: England
ID NLM: 0370635
Informations de publication
Date de publication:
04 Sep 2024
04 Sep 2024
Historique:
received:
13
05
2024
accepted:
23
08
2024
revised:
16
08
2024
medline:
5
9
2024
pubmed:
5
9
2024
entrez:
4
9
2024
Statut:
aheadofprint
Résumé
Comorbidities have been shown to impact the presentation and treatment of patients with cancers. This study investigates the prevalence and patterns of comorbidity in a pan-cancer cohort of patients treated at a large UK specialist cancer center over a 9-year period. A retrospective review of 77,149 patients from 01/01/2014 to 15/12/2022 was conducted using the Adult Comorbidity Evaluation 27 score (ACE-27) to assess the burden of comorbidities across 12 organ systems and an overall comorbidity burden. Binary and multinomial logistic regressions were utilized to evaluate the relationships between comorbidity incidence and demographic and socio-economic factors. At the time of diagnosis, 59.7% of patients had at least one comorbidity, with the highest prevalence in lung cancer and the lowest in brain/CNS and endocrine gland cancers. Cardiovascular comorbidities were the most frequent. Comorbidity severity was higher in patients from more deprived areas. Age and performance status were associated with a higher incidence of all comorbidities examined. Patients with advanced stage had a lower risk of having a severe comorbidity burden. Comorbidities are common across all cancers but are more prevalent in certain patient populations. Further research to understand the implications of comorbidities in cancer management is needed.
Sections du résumé
BACKGROUND
BACKGROUND
Comorbidities have been shown to impact the presentation and treatment of patients with cancers. This study investigates the prevalence and patterns of comorbidity in a pan-cancer cohort of patients treated at a large UK specialist cancer center over a 9-year period.
METHODS
METHODS
A retrospective review of 77,149 patients from 01/01/2014 to 15/12/2022 was conducted using the Adult Comorbidity Evaluation 27 score (ACE-27) to assess the burden of comorbidities across 12 organ systems and an overall comorbidity burden. Binary and multinomial logistic regressions were utilized to evaluate the relationships between comorbidity incidence and demographic and socio-economic factors.
RESULTS
RESULTS
At the time of diagnosis, 59.7% of patients had at least one comorbidity, with the highest prevalence in lung cancer and the lowest in brain/CNS and endocrine gland cancers. Cardiovascular comorbidities were the most frequent. Comorbidity severity was higher in patients from more deprived areas. Age and performance status were associated with a higher incidence of all comorbidities examined. Patients with advanced stage had a lower risk of having a severe comorbidity burden.
CONCLUSION
CONCLUSIONS
Comorbidities are common across all cancers but are more prevalent in certain patient populations. Further research to understand the implications of comorbidities in cancer management is needed.
Identifiants
pubmed: 39232185
doi: 10.1038/s41416-024-02838-w
pii: 10.1038/s41416-024-02838-w
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Søgaard M, Thomsen RW, Bossen KS, Sørensen HT, Nørgaard M. The Impact of Comorbidity on Cancer Survival: A Review. Clin Epidemiol. 2013;5:3–29. https://doi.org/10.2147/clep.s47150 .
doi: 10.2147/clep.s47150
pubmed: 24227920
pmcid: 3820483
Jakovljević M, Ostojić L. Comorbidity and Multimorbidity in Medicine Today: Challenges and Opportunities for Bringing Separated Branches of Medicine Closer to Each Other. Psychiatr Danubina. 2013;25:18–28.
Gurney J, Sarfati D, Stanley J. The Impact of Patient Comorbidity on Cancer Stage at Diagnosis. Br J Cancer. 2015;113:1375–80. https://doi.org/10.1038/bjc.2015.355 .
doi: 10.1038/bjc.2015.355
pubmed: 26461060
pmcid: 4815795
Mounce LTA, Price S, Valderas JM, Hamilton W. Comorbid Conditions Delay Diagnosis of Colorectal Cancer: A Cohort Study Using Electronic Primary Care Records. Br J Cancer. 2017;116:1536–43. https://doi.org/10.1038/bjc.2017.127 .
doi: 10.1038/bjc.2017.127
pubmed: 28494470
pmcid: 5518856
Terret C, Castel-Kremer E, Albrand G, Droz JP. Effects of Comorbidity on Screening and Early Diagnosis of Cancer in Elderly People. Lancet Oncol. 2009;10:80–7. https://doi.org/10.1016/s1470-2045(08)70336-x .
doi: 10.1016/s1470-2045(08)70336-x
pubmed: 19111248
Piccirillo JF, Feinstein AR. Clinical Symptoms and Comorbidity: Significance for the Prognostic Classification of Cancer. Cancer. 1996;77:834–42. https://doi.org/10.1002/(SICI)1097-0142(19960301)775<834::AID-CNCR5>3.0.CO;2-E .
doi: 10.1002/(SICI)1097-0142(19960301)775<834::AID-CNCR5>3.0.CO;2-E
pubmed: 8608472
Extermann M, Overcash J, Lyman GH, Parr J, Balducci L. Comorbidity and Functional Status Are Independent in Older Cancer Patients. J Clin Oncol. 1998;16:1582–7. https://doi.org/10.1200/jco.1998.16.4.1582 .
doi: 10.1200/jco.1998.16.4.1582
pubmed: 9552069
Siembida EJ, Smith AW, Potosky AL, Graves KD, Jensen RE. Examination of Individual and Multiple Comorbid Conditions and Health-Related Quality of Life in Older Cancer Survivors. Qual Life Res. 2021;30:1119–29. https://doi.org/10.1007/s11136-020-02713-0 .
doi: 10.1007/s11136-020-02713-0
pubmed: 33447956
pmcid: 7808400
Gallagher EJ, LeRoith D. Obesity and Diabetes: The Increased Risk of Cancer and Cancer-Related Mortality. Physiological Rev. 2015;95:727–48. https://doi.org/10.1152/physrev.00030.2014 .
doi: 10.1152/physrev.00030.2014
Fowler H, Belot A, Ellis L, Maringe C, Luque-Fernandez MA, Njagi EN, et al. Comorbidity Prevalence among Cancer Patients: A Population-Based Cohort Study of Four Cancers. BMC Cancer. 2020;20:2 https://doi.org/10.1186/s12885-019-6472-9 .
doi: 10.1186/s12885-019-6472-9
pubmed: 31987032
pmcid: 6986047
Balic M, Hilbe W, Gusel S, Fiegl M, Ludwig H, Mayrbäurl B, et al. Prevalence of Comorbidity in Cancer Patients Scheduled for Systemic Anticancer Treatment in Austria. memo Mag Eur Med Oncol. 2019;12:290–6. https://doi.org/10.1007/s12254-019-00542-7 .
doi: 10.1007/s12254-019-00542-7
Tsilidis KK, Kasimis JC, Lopez DS, Ntzani EE, Ioannidis JP. Type 2 Diabetes and Cancer: Umbrella Review of Meta-Analyses of Observational Studies. BMJ. 2015;350:g7607 https://doi.org/10.1136/bmj.g7607 .
doi: 10.1136/bmj.g7607
pubmed: 25555821
Sarfati D, Koczwara B, Jackson C. The Impact of Comorbidity on Cancer and Its Treatment. CA Cancer J Clin. 2016;66:337–50. https://doi.org/10.3322/caac.21342 .
doi: 10.3322/caac.21342
pubmed: 26891458
Duma N, Kothadia SM, Azam TU, Yadav S, Paludo J, Vera Aguilera J, et al. Characterization of Comorbidities Limiting the Recruitment of Patients in Early Phase Clinical Trials. Oncologist. 2019;24:96–102. https://doi.org/10.1634/theoncologist.2017-0687 .
doi: 10.1634/theoncologist.2017-0687
pubmed: 30413668
Klepin HD, Pitcher BN, Ballman KV, Kornblith AB, Hurria A, Winer EP, et al. Comorbidity, Chemotherapy Toxicity, and Outcomes among Older Women Receiving Adjuvant Chemotherapy for Breast Cancer on a Clinical Trial: Calgb 49907 and Calgb 361004 (Alliance). J Oncol Pr. 2014;10:e285–92. https://doi.org/10.1200/jop.2014.001388 .
doi: 10.1200/jop.2014.001388
Nguyen SM, Pham AT, Nguyen LM, Cai H, Tran TV, Shu XO, et al. Chemotherapy-Induced Toxicities and Their Associations with Clinical and Non-Clinical Factors among Breast Cancer Patients in Vietnam. Curr Oncol. 2022;29:8269–84. https://doi.org/10.3390/curroncol29110653 .
doi: 10.3390/curroncol29110653
pubmed: 36354713
pmcid: 9689154
Chao C, Page JH, Yang SJ, Rodriguez R, Huynh J, Chia VM. History of Chronic Comorbidity and Risk of Chemotherapy-Induced Febrile Neutropenia in Cancer Patients Not Receiving G-Csf Prophylaxis. Ann Oncol. 2014;25:1821–9. https://doi.org/10.1093/annonc/mdu203 .
doi: 10.1093/annonc/mdu203
pubmed: 24915871
Piccirillo JF, Tierney RM, Costas I, Grove L, Spitznagel JEL. Prognostic Importance of Comorbidity in a Hospital-Based Cancer Registry. JAMA. 2004;291:2441–7. https://doi.org/10.1001/jama.291.20.2441 .
doi: 10.1001/jama.291.20.2441
pubmed: 15161894
Sarfati D. Review of Methods Used to Measure Comorbidity in Cancer Populations: No Gold Standard Exists. J Clin Epidemiol. 2012;65:924–33. https://doi.org/10.1016/j.jclinepi.2012.02.017 .
doi: 10.1016/j.jclinepi.2012.02.017
pubmed: 22739245
Adult Co-Morbidity Evaluation (Ace-27) Uk Values. Available from: https://www.rcplondon.ac.uk/file/3058/download .
Sarfati D, Gurney J, Lim BT, Bagheri N, Simpson A, Koea J, et al. Identifying Important Comorbidity among Cancer Populations Using Administrative Data: Prevalence and Impact on Survival. Asia Pac J Clin Oncol. 2016;12:e47–56. https://doi.org/10.1111/ajco.12130 .
doi: 10.1111/ajco.12130
pubmed: 24354451
McLean G, Gunn J, Wyke S, Guthrie B, Watt GC, Blane DN, et al. The Influence of Socioeconomic Deprivation on Multimorbidity at Different Ages: A Cross-Sectional Study. Br J Gen Pract. 2014;64:e440–7. https://doi.org/10.3399/bjgp14X680545 .
doi: 10.3399/bjgp14X680545
pubmed: 24982497
pmcid: 4073730
McLennan D, Noble S, Nobel M, Plunkett E, Wright G, Gutacker N. The English Indices of Deprivation: Technical Report”, Ministry of Housing, Communities and Local Government. 2019. Available from: https://www.gov.uk/government/publications/english-indices-of-deprivation-2019-technical-report .
National Disease Registration Service. 2024. Available from: https://nhsd-ndrs.shinyapps.io/cancers_by_diagnosis_trust/ .
Wolfenden HH. On the Methods of Comparing the Moralities of Two or More Communities, and the Standardization of Death-Rates. J R Stat Soc. 1923;86:399–411. https://doi.org/10.2307/2341622 .
doi: 10.2307/2341622
Everitt B, Landau S, Leese M, Stahl D. Cluster Analysis. Wiley Series in Probability and Statistics, Chichester, West Sussex, UK; 2011. https://doi.org/10.1002/9780470977811 .
The Christie Nhs Foundation Trust. 2024. Available from: https://en.wikipedia.org/wiki/The_Christie_NHS_Foundation_Trust .